Clinical Trial

Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer

Study acronym: LOTS
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This open-label, Phase I/II trial is studying the safety and effectiveness of an experimental drug combination, lurbinectedin with osimertinib, against a rare type of cancer known as transformed small cell lung cancer (SCLC).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-08-26; most recent amendment 2026-06-16.
Status change: Not Yet Recruiting → Recruiting 2026-06-16
Trial Details
NCT Number NCT07153055
Lead Sponsor Misty Shields
Collaborators: Jazz Pharmaceuticals
Conditions Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer
Enrollment 16 participants
Start Date 2026-08
Primary Completion 2029-04 (estimated)
Study Completion 2029-10 (estimated)
Updated on ClinicalTrials.gov 2026-06-18